Plasma therapy not beneficial against coronavirus: ICMR fund
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Use of convalescent plasma therapy in COVID-19 patients do not help in reducing mortality or progression to a severe case of COVID-19, a multi-centric study funded by the Indian Council of Medical Research (ICMR) has found.

The trial, called PLACID, was carried out under the aegis of Indian Council of Medical Research in 39 hospitals across 14 states and Union Territories, to find the effectiveness of convalescent plasma (CP) for the treatment of COVID-19

Key Insights:

• Study included 464 moderately ill coronavirus infected hospitalised patients (PaO2/FiO2: 200-300 or respiratory rate > 24/min and SpO2 ? 93% on room air).

• 235 were given convalescent plasma along with best of standard care while 229 received only standard care.

• Those in the intervention arm received two doses of 200 ml of CP, transfused 24 hours apart, in addition to the BSC (best standard of care).

• 34 patients or 13.6 % who received plasma therapy died while 31 patients or 14.6 % who did not receive it, succumbed to the infection. Also, 17 patients in each group progressed to have severe disease.

• Interpretation: CP was not associated with a reduction in mortality or progression to severe COVID-19.

These findings assume immense significance as several state governments have actively promoted the therapy and have set up plasma banks after the national Covid-19 clinical management protocol allowed it as an investigational therapy.

Dr. T●●●●z H●●●●●●i and 6 others like this15 shares